Carol D. Karp - Sep 9, 2021 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role: Chief Regulatory Officer
Signature: /s/ Michael Malecek, as Attorney in Fact for Carol D. Karp
Stock symbol: PRTA
Transactions as of: Sep 9, 2021
Transactions value $: -$569,447
Form type: 4
Date filed: 9/10/2021, 05:06 PM
Next filing: Oct 1, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Options Exercise	$150K	+10K		$15.04^*	10K	Sep 9, 2021	Direct
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	-$390K	-5.46K	-54.58%	$71.45	4.54K	Sep 9, 2021	Direct	F1, F2
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	-$330K	-4.54K	-100%	$72.63	0	Sep 9, 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRTA	Stock Option (Right to Buy)	Options Exercise	$0	-10K	-6.67%	$0.00	140K	Sep 9, 2021	Ordinary Shares	10K	$15.04	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The transaction was executed in multiple trades in prices ranging from $70.94 to $71.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3	The transaction was executed in multiple trades in prices ranging from $72.16 to $72.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4	The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.